{"entity":{"id":"amir-iravani","kind":"person","name":"Amir Iravani","aka":[],"tldr":"A nuclear medicine physician-scientist who worked on the practice-changing TheraP and LuPSMA trials in Australia and has moved through Fred Hutchinson to UCLA in 2026 to build a new hospital theranostics programme.","summary":"Amir Iravani trained at Melbourne's Peter MacCallum Cancer Centre, where he was a co-investigator on the LuPSMA phase 2 trial and the TheraP randomised phase 2 trial (177Lu-PSMA-617 versus cabazitaxel), including work on PSMA and FDG PET as predictive and prognostic biomarkers. He later became Theranostics Clinical Director at Fred Hutchinson Cancer Center and Associate Professor of Radiology at the University of Washington, where he studied how PSMA/FDG dual-tracer selection criteria (TheraP-style versus VISION-style) affect outcomes with 177Lu-PSMA-617.\n\nIn July 2026 he joined UCLA Health as Director of the Theranostics Program and Vice Chair of Clinical Research in the newly established Department of Nuclear Medicine and Theranostics, tasked with expanding clinical trials and research collaborations in precision radiopharmaceutical care.","asOf":"2026-09-22","links":[{"label":"UCLA Health news release, September 2026","url":"https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins"},{"label":"Becker's Hospital Review coverage","url":"https://www.beckershospitalreview.com/radiology/ucla-health-taps-fred-hutch-theranostics-leader/"}],"tags":["PSMA","theranostics","clinician"],"related":["therap","pluvicto","ucla-jonsson","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor and Vice Chair of Clinical Research, Director of the Theranostics Program, Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA (from July 2026; previously Theranostics Clinical Director, Fred Hutchinson Cancer Center, and Associate Professor of Radiology, University of Washington, 2022-2026)","specialisms":["PSMA radioligand therapy trials","dosimetry","dual-tracer (PSMA/FDG) patient selection"],"profiles":[{"label":"UW Radiology profile (2022-2026)","url":"https://rad.uw.edu/people/airavani"},{"label":"UCLA Health announcement, September 2026","url":"https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins"}],"papers":[{"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","journal":"The Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00237-3"},{"title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30198-0"},{"title":"PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268578"}]},"route":"/people/amir-iravani/","neighbours":{"trial":[{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"person":[{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/"}]}}